by Elena Iemma | Apr 21, 2025 | News
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ — EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling...
by Elena Iemma | Feb 27, 2025 | News
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
by Elena Iemma | Dec 9, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth....
by Elena Iemma | Dec 6, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, a leader in biotechnology known for its advanced immunoinformatics tools, proudly announces its continued support for two nonprofits, Clínica Esperanza/Hope Clinic and GAIA Vaccine Foundation....
by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Elena Iemma | Oct 18, 2024 | Events, News
The 10th annual Amsterdam Immunogenicity and Tolerance Seminar was a fantastic success, bringing together a passionate group of immunology and vaccinology experts to explore new frontiers in the field. The morning sessions focused on protein therapeutics, with...
